Allogene Therapeutics (ALLO) Gets a Buy from Piper Sandler
In a report released today, Biren Amin from Piper Sandler maintained a Buy rating on Allogene Therapeutics (ALLO – Research Report), with a ...
William Blair Sticks to Its Buy Rating for Allogene Therapeutics (ALLO)
In a report released today, Sami Corwin from William Blair maintained a Buy rating on Allogene Therapeutics (ALLO – Research Report). The ...
Allogene reports promising results for CAR T therapy in lymphoma
SOUTH SAN FRANCISCO - Allogene Therapeutics, Inc. (NASDAQ:ALLO), a biotechnology firm specializing in allogeneic CAR T therapies currently valued at approximately $299 million, has published new data ...